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Abstract
Background and Objective: Analysis of inflammatory biomarkers in saliva could offer an attractive opportunity for the
diagnosis of different systemic conditions specifically in epidemiological surveys. The aim of this study was to investigate if
certain salivary biomarkers could be used for detection of common systemic diseases.
Materials and Methods: A randomly selected sample of 1000 adults living in Ska˚ne, a county in the southern part of
Sweden, was invited to participate in a clinical study of oral health. 451 individuals were enrolled in this investigation, 51%
women. All participants were asked to fill out a questionnaire, history was taken, a clinical examination was made and
stimulated saliva samples were collected. Salivary concentrations of IL-1b, -6, -8, TNF-a, lysozyme, MMP-8 and TIMP-1 were
determined using ELISA, IFMA or Luminex assays.
Results: Salivary IL-8 concentration was found to be twice as high in subjects who had experience of tumour diseases. In
addition, IL-8 levels were also elevated in patients with bowel disease. MMP-8 levels were elevated in saliva from patients
after cardiac surgery or suffering from diabetes, and muscle and joint diseases. The levels of IL-1b, IL-8 and MMP-8, as well as
the MMP-8/TIMP-1 ratio were higher in subjects with muscle and joint diseases.
Conclusion: Biomarkers in saliva have the potential to be used for screening purposes in epidemiological studies. The
relatively unspecific inflammatory markers used in this study can not be used for diagnosis of specific diseases but can be
seen as markers for increased systemic inflammation.
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Introduction
Analysis of inflammatory biomarkers in saliva could offer an
attractive solution for the diagnosis of different systemic conditions
in epidemiological surveys.
Human saliva is composed of 98% water and 2% other
compounds, such as electrolytes, mucus, antibacterial compounds,
and various enzymes. Multiple functions of saliva include rinsing,
solubilisation of food substances, food and bacterial clearance,
lubrication of soft tissues, bolus formation, swallowing, speech and
facilitation of mastication, all of which are related to its fluid
characteristics and specific components. In addition, saliva
components contribute to mucosal coating, digestion and
antibacterial defence [1].
Several types of inflammatory biomarkers associated with both
oral diseases, as well as systemic diseases have been detected in
saliva, such as interleukins-1b, -6 and -8 (IL-1b, -6 and -8), tumour
necrosis factor-a (TNF-a) and matrix metalloproteinases (MMP)-8
and -9 [2,3,4,5,6]. An increasing number of specific molecular
markers for different diseases, such as oral and breast cancer,
cardiovascular diseases and human immunodeficiency virus (HIV)
are being identified [7,8,9].
IL-1b is a pro-inflammatory cytokine released by different cells
in the inflammatory lesion, and IL-6 has both pro-inflammatory
and anti-inflammatory actions [10,11]. It can induce B and T- cell
growth and differentiation, and acute- phase protein induction. IL-
8 is a chemokine, mainly produced by macrophages and epithelial
cells upon inflammatory stimulation. IL-8 plays a causative role in
the acute inflammatory phase by activating neutrophils and thus
has an important role in the inflammatory response [12,13]. TNF-
a plays a vital role as a pro-inflammatory and immune-regulatory
cytokine [14]. MMP-8 or collagenase-2 derived mainly from
polymorphonuclear leukocytes (PMN) is particularly released
during the acute phase of inflammatory diseases [15]. It is known
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that MMP-8 is involved in the pathogenesis of coronary artery
diseases. Activation of MMPs plays an important role in infarction
evolution as well as in tissue repairing processes and cardiac
remodelling [16,17]. As a result of acute myocardial infarction, a
reparative process is initiated by infiltration of inflammatory cells,
MMP activation, remodelling of extracellular matrix and scar
formation [18]. MMP-8 and tissue inhibitor of MMP (TIMP) -1
concentrations have been associated with ischemia and infarction
[19]. The initiation of collagen degradation from the connective
tissue and alveolar bone occurs due to an imbalance between
MMPs and their inhibitors TIMPs [20]. TIMP-1 is a major
endogenous inhibitor of MMP-8. MMP-8 and TIMP-1 levels, as
well as the MMP-8/TIMP-1 ratio in serum reflect progression and
severity of cardiovascular diseases [21,22]. Additional enzymes
that are involved have been identified in saliva include lysozymes,
which are also abundant in a number of other secretions, such as
tears and mucus. Lysozymes are glycoside hydrolases and part of
the innate immune system. Furthermore, one of the main
properties of lysozymes is their ability to bind to hydroxyapatite,
which suggests an antimicrobial role on the tooth surface [23].
IL-1b, MMP-8 and TNF-a have been shown to be elevated in
the inflamed joints and serum of patients with rheumatoid arthritis
[24]. Another study showed that the salivary levels of IL-1b which
was the only biomarker, was significantly higher in the arthritis
group compared to the control group [25].
With this background we wish to test the hypothesis that certain
salivary biomarkers could be used for the detection of systemic
diseases, with particular relevance to epidemiological studies.
Special attention was addressed to the effects of smoking on
potential salivary inflammatory biomarkers.
Materials and Methods
Participants
A randomly selected sample of 1000 adults living in Ska˚ne, a
county in the southern part of Sweden, was invited to participate
in a clinical study of oral health. The individuals were between 20
and 89 years old and were registered living in Ska˚ne during 2007.
The participant list was obtained from SPAR (The Swedish
Government’s Person Address Register) and included background
variables, such as gender, domicile, address and age in 5-year-
intervals. All participants gave their written informed consent to
the study protocol, which had been approved by the Ethical Board
(Dnr 513/2006) at the University of Lund, Sweden. Of the
original sample, 11 individuals had moved from the region, 14 had
an unknown address and nine were deceased, thus leaving 966
individuals as the initial sample. In total, 448 individuals were
examined clinically, 230 (51%) women and 218 (49%) men (Figure
S1 in File S1). The clinical examinations were performed between
March 2007 and November 2008, and took place at the Faculty of
Odontology at Malmo¨ University, Sweden, and at three clinics
belonging to the Public Dental Service in Helsingborg, Kristian-
stad and Ystad, all in Ska˚ne [26].
Questionnaire
All the clinically examined participants were asked to respond to
a questionnaire, and only one failed to answer. This questionnaire
contained 58 questions concerning patient perception of oral
health, oral healthcare needs, pain, the use of oral healthcare,
dental materials and background factors [27]. Anamnestic data,
including diseases, use of medication, smoking and the use of
Swedish snus were collected. Patients who were not able to or were
not interested in being clinically examined were contacted by
telephone in order to be part of a non-response analysis, and 175
of these individuals answered the same questionnaire as the
individuals participating in the clinical study. Individuals who
filled in the questionnaire as a non-response analysis were more
likely to be born in Sweden, have a lower educational level and
were missing a higher number of teeth than those participating in
the clinical study. These differences can most likely be explained
by the fact that the non-response group included most of the oldest
individuals compared to the clinical study. The individuals, who
neither participated in the clinical examination nor answered the
questionnaire, were those who could not be reached by telephone
or letter, were unable to take part due to bad health, due to old age
or were simply not interested in participating in this study.
Salivary Sampling
Stimulated saliva was collected during 5 min chewing on 0.5 g
of paraffin, into a graded test-tube. The collected amount was
determined, excluding the foam, and the secretion rate per minute
was recorded. Trained dental assistants performed saliva sampling
and scoring of results. Collected samples were immediately frozen
at 220uC until processing. The saliva samples were collected in
15 ml Falcon tubes (kolla artikelnumret!) and kept frozen at
220uC until further processed. The samples were then thawed
and centrifuged at 500 g for 10 minutes at 4uC. The supernatants
were collected and divided into several aliquots that were quick-
frozen and stored at 280uC until analysis. Each aliquot was used
only once in an assay, and then discarded. The pellets, containing
whole cells, were resuspended in 200 ul PBS and transferred to a
1.5 ml Eppendorf tube (Eppendorf, Hauppauge, NY, USA), and
immediately frozen and stored at 280uC.
Biomarker Analysis
MMP-8 was analysed by a time-resolved immunofluorometric
assay. Monoclonal MMP-8- antibodies 8708 and 8706 (Medix
Biochemica, Kauniainen, Finland) were used as capture antibodies
and tracer antibodies respectively. The tracer antibody (8706) was
labelled using europium (Eu)-chelate and the assay buffer
contained 20 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 5 mM CaCl2
50 lM ZnCl2, 0.5% bovine serum albumin, 0.05% sodium azide
and 20 mg/l diethylenetriaminepentaacetic acid. Saliva samples
were diluted in assay buffer and incubated for 1 h, followed by
incubation for a further 1 h with tracer antibody. Enhancement
solution was added, and after 5 min, fluorescence was measured
using a 1234 Delfia Research Fluorometer (Wallac, Turku,
Finland) [20,28]. The concentration of capture antibody (8708)
in the MMP-8/IFMA assay was 2.25 ug/well, and the concen-
tration of the tracer Eu-lablled MMP-8 antibody (8706) was
0.5 ug/well. MMP-8 had a detection limit of 0.08 ng/ml and a
coefficient of variation of 7.3%. TIMP-1 (Amersham Biotrak, GE
Healthcare, Buckinghamshire, UK) was analysed by an enzyme-
linked immunosorbent assay (ELISA) kits according to the
manufacturer’s instructions. The inter-assay coefficient of varia-
tion for TIMP-1 was 8.2% and the detection limit for the assay
was 1.25 ng/ml. Concentrations of salivary TNF-a, IL-1b, IL-6
and IL-8 were determined by using a Luminex multiplex kit
(BioRAD, Hercules, CA, USA). Lysozyme was analysed with
ELISA kit (R&D Systems, Minneapolis, MN, USA). The detection
limits for analysed cytokines were as follows: TNF-a 1.2 pg/ml,
IL-1b 0.5 pg/ml, IL-6 0.5 pg/ml and IL-8 0.5 pg/ml and for
lysozyme 1.25 ng/ml. Sample analyses were performed at the
Department of Dental Medicine, Karolinska Institutet. The total
protein concentration was determined using the Bradford assay.
The amounts of the analysed substances were expressed as ng or
pg per ml of centrifuged saliva.
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Statistical Analysis
Data analyses were performed using Statistical Package for
Social Sciences (SPSS) version 21 (SPSS Inc., Chicago, IL). The p-
value #0.05 was considered as significant. The significances of the
differences in biomarker concentration between smoker/non-
smoker, men/women and between those suffering with or without
the indicated disease were calculated with Students t-test. The
significance of the differences after compensation for age, gender
and smoking was performed using the General Linear Model. The
correlation between age and biomarker concentration was
calculated with Pearson Product Moment Correlation. Values
under the detection limit were not included into the statistical
analysis.
Results
The characteristics of the study population (age, smoking, and
systemic conditions) are presented in Table S1 in File S2. The
mean age was higher in the male subjects. The percentage of
tobacco smoking, heart surgery, heart disease, hypertension and
bowel diseases were also higher in males. In female subjects, a
number of conditions were found to be more prevalent, for
example diabetes, muscle and joint diseases, tumours and mental
disorders.
The analysed biomarkers were detected in more than 99% of
the samples, except for TNF-a whose concentration was below the
detection level in more than 50% of the samples. Table S2 in File
S2 shows the influence of gender, smoking and age on the
concentration of analysed inflammatory biomarkers (IL-1b, -6, -8,
TNF-a, lysozyme, MMP-8, TIMP-1 and total protein concentra-
tion). Salivary concentrations of IL-1b, and IL-8 were higher in
male subjects compared to the female subjects or otherwise there
were no gender related differences. Furthermore, the levels of IL-
8, MMP-8, the ratio of MMP-8/TIMP-1 and the total protein
concentration were higher in smokers. Finally, all the analysed
biomarkers, except IL-6 and TIMP-1, correlated significantly with
the variable age.
Tables S3a, S3b and S3c in File S3 illustrate mean concentra-
tions and standard deviations of analysed biomarkers in stimulated
saliva samples from 441 subjects. The analysed biomarkers did not
differ between those who answered that they had heart disease and
those who did not. However, the 11 patients that had undergone
heart surgery had higher concentrations of MMP-8. This
difference also remained after compensation for age, gender and
smoking habits. Patients reporting high blood pressure presented
with higher concentrations of MMP-8 and lysozyme, as well as an
increased MMP-8/TIMP-1 ratio but these differences were lost
after compensation for age, gender and smoking habits.
Patients with diabetes had higher concentrations of MMP-8 and
a higher MMP-8/TIMP-1 ratio. These differences were more
pronounced after compensation for age, gender and smoking.
Bowel disease was associated with elevated concentrations of IL-8
and total protein. Muscle and joint diseases were associated with
increased IL-1b, MMP-8 and the ratio MMP-8/TIMP-1. Patients
who responded that they were or had been suffering from any kind
of tumour had more than twice the concentration of IL-8
compared to those who had not had tumours. This difference
was significant and remained after compensation. Mental illness
could not be associated with any of the analysed biomarkers.
Variable inflammation, which could include a combination of
systemic conditions like heart disease, high blood pressure, bowel
disease, and muscle and joint diseases, was associated with
increased concentrations of IL-8, MMP-8, MMP-8/TIMP-1 ratio,
lysozyme and total protein. Out of the above mentioned
conditions only the total protein concentration difference re-
mained significant after compensation for age, gender and
smoking.
Discussion
Saliva is a unique fluid that can be used to monitor both oral
and systemic health. In the present study, salivary levels of IL-1b, -
6 -8, TNF-a, MMP-8, TIMP-1 and lysozyme were determined in
a population of 441 adults. It shows that several common diseases
or conditions can be associated with the studied biomarkers in
saliva, supporting our hypothesis. Indeed, the numerically
recovered biggest differences between patients with or without
the studied diseases were specifically found for diabetes and
tumour diseases.
Patients with diabetes had a three times higher ratio of MMP-8/
TIMP-1 and twice as high concentration of MMP-8. Increased
MMP-8 levels in association with diabetes have earlier been shown
in saliva, gingival crevicular fluid and in gingival tissues [29,30,31].
Increased concentrations of MMP-8 have been associated with an
increased inflammatory process in patients with diabetes [32].
Salivary IL-8 concentration was found to be twice as high in
patients with experience of tumour diseases compared to subjects
who had not suffered. This difference was significant even after
compensation for differences in age, gender and smoking habits.
Our finding is in line with a study performed by Wei and co-
authors that investigated salivary IL-8 levels of patients with oral
cancer [33]. A recent study by Punyani and Sathawane [34]
suggested that salivary IL-8 had the potential to be biomarker for
oral squamous cell carcinoma (OSCC). An earlier study using
transcriptome analyses also showed 91% sensitivity for IL-8 as a
marker for OSCC [35]. In addition, IL-8 has been shown to be
elevated in both serum and saliva in patients with head and neck
squamous cell cancer [36]. Interestingly, in the current study, IL-8
was also raised in patients who reported bowel disease, and muscle
and joint diseases.
In recent years a possible role for MMPs in atherosclerosis
development has been described [37]. MMP-8 is reported to be
associated with both atherosclerosis and metabolic syndrome
[38,39,40]. Elevated salivary levels of MMP-8 have been linked
with an increased risk for cardiovascular disease [41]. In our study,
participants who responded that they had heart disease did not
have elevated concentrations of MMP-8. Nevertheless, those who
had underwent heart surgery (n = 11) had significantly higher
MMP-8 concentrations in their saliva.
In earlier publications, oral infections, hyperglycemia, hyper-
tension and metabolic syndrome show a significant association
with increased salivary levels of lysozyme [42,43]. In our
investigation, lysozyme concentration was higher in the saliva of
patients reporting inflammatory conditions and/or high blood
pressure. The significance of these associations disappeared after
compensation for differences in gender, age and smoking habits
between the groups.
Oral infections, such as periodontal disease could have also
influenced our findings as periodontal disease has been associated
with conditions like cardiovascular disease, diabetes mellitus and
rheumatoid arthritis [44,45,46]. Salivary biomarkers such as IL-
1b, MMP-8 and the ratio of MMP-8/TIMP-1 correlated
significantly with clinical variables like pocket depth and bleeding
on probing, which could reflect the degree of periodontal/gingival
inflammation [47]. Further, IL-1b could be seen as a general
marker of inflammation but it remains to be determined if it is
possible to differentiate between gingivitis and periodontitis.
Higher salivary concentration of IL-1b from patients with
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periodontitis has been detected in several earlier studies
[48,49,50]. A study performed by Kinney et al. reported that
IL-1b and MMP-8 strongly correlated with periodontal disease
status [51].
In this study we chose to relate the amounts of the analysed
proteins to the volume rather than to the protein content. Our
study indicates that certain biomarkers in saliva exhibit a potential
to be used for screening purposes in epidemiological studies.
Conversely, it is important to consider that both IL-1b and MMP-
8 are general markers for both local and systemic inflammations
and seemingly cannot be used for diagnosis of specific diseases.
The mean value of MMP-8 was more than 50% higher in patients
with one or several inflammatory conditions (heart disease, high
blood pressure, bowel disease, and muscle and joint diseases).
Additional investigations are warranted to develop tools for
diagnosis and intervention selection, as well as for screening
purposes [30].
This study has some limitations that must be considered when
interpreting the findings: the medical status is based on the
participants self-assessment and no verification of the answers from
the anamnestic data. There is an obvious risk for false negatives,
for instance undiagnosed diseases. In addition, due to the large
number of comparisons in regard to different systemic conditions,
compensation for this will eliminate all significances. However, this
study is meant as a survey to generate hypotheses.
Since the inflammatory markers analysed in this study are
general, more specific markers would be required to achieve an
acceptable specificity. A combination of markers was probably
necessary for several diseases [52]. Furthermore, the biomarkers
obtained from the saliva samples depend upon the biochemical
nature of the marker, the source and type of sample being taken,
the assay reagents and techniques used [41,53], and the
mechanism by which the marker enters the oral cavity [54].
In conclusion, saliva-based clinical testing could provide a
potential diagnostic tool for the detection of certain diseases and
conditions using biomarkers associated with enhanced systemic
inflammation. Although limited by the study design, additional
research in this area is required to strengthen this assessment.
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